Cedara results boom as new CFO named
On the financial ropes less than two years ago, Cedara Software is fighting back. The company achieved a 50% boost in revenues in the three months ended March 31 to $13.5 million compared with $9 million in the third quarter of 2003. Net income for the
On the financial ropes less than two years ago, Cedara Software is fighting back. The company achieved a 50% boost in revenues in the three months ended March 31 to $13.5 million compared with $9 million in the third quarter of 2003. Net income for the quarter was $5.1 million, compared with a net loss of $1.6 million in 3Q the previous year. Contributing heavily to the company's improved financial picture were three major agreements Cedara struck with OEMs. Revenues from one of these were recognized in the recent third quarter. Substantial revenues from the other two are likely to be recognized next quarter. In reporting the financial results, Cedara announced the appointment of Brian Pedlar as chief financial officer. He previously served as Cedara's director of finance and administration.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
